-
Cochin Shipyard
2,377.00 2,977.10(%) -
Garden Reach Sh.
3,528.00 3,528.00(%) -
Reliance Power
59.93 23.26(%) -
Mazagon Dock
3,460.00 3,778.00(%) -
Brainbees Solut.
410.00 734.25(%) -
Suzlon Energy
68.60 86.04(%) -
Eternal Ltd
260.15 304.50(%) -
Tata Motors
714.00 1,179.05(%) -
Sika Interplant
1,350.35 1,350.35(%) -
Angel One
3,283.00 3,502.60(%) -
Data Pattern
3,208.90 3,654.75(%) -
Reliance Industr
1,454.50 1,608.95(%) -
Bharat Electron
394.60 394.60(%) -
Waaree Energies
2,838.05 1,808.65(%) -
Newgen Software
1,335.70 1,795.50(%) -
Bharat Dynamics
1,981.00 2,096.00(%) -
Railtel Corpn.
464.70 618.00(%) -
Avantel
184.50 212.68(%) -
I R F C
148.00 229.05(%) -
Ircon Intl.
216.70 134.30(%)
- Overview
- Key Ratios
- Financials
- Shareholding
- Company Info
- Peer Comparison
- Overview
- Key Ratios
- Financials
- Shareholding
- Company Info
- Peer Comparison
Zydus Lifesciences Ltd Pharmaceuticals - Indian - Bulk Drugs & Formln
- Cadila
- BSE Code : 20883.0
- ISIN : INE010B01027
-
Today’s Low
933.00 -
Today’s High
958.25

-
Open
933.00 -
Perv Close
931.50 -
52W Low
795.00 -
52W High
1,324.30
Key Indicators
-
P/E(TTM)
16.65
-
Mar.Cap (₹Cr.)
96,165.78
-
Div & Yield %
1.15
-
Book Value(₹)
210.59
-
Debt-Equity Ratio
2.60
-
AGM Date
05-Jun-2025
-
EPS
57.39
-
P/E Ratio
16.65
Financials Ratios
-
Debt-Equity Ratio
0.05
-
Mar.Cap (₹Cr.)
96,165.78
-
RONW (%)
20.64
-
ROCE (%)
23.94
Score Board
-
Equity (₹ in Cr.)
100.62
-
BV (₹)
210.60
-
Sales( ₹ in Cr.)
14,590.10
-
NP (in Cr.)
5,774.90
-
NP Var(%)
68.0
-
Div%
1100.0
-
CPS (₹)
62.60
-
EPS (₹)
57.40
-
Traded Value (₹ in Lakhs)
96,155.72
-
52 Week High
1,324.30
-
52 Week Low
795.00
-
Price BSE
956.0
-
Price NSE
956.00
-
Market Capital( in Cr.)
96,155.72
-
P/C Ratio
15.30
-
P/E Ratio
16.70
-
Price Vs.BV
57.40
-
02-Jun-2025( 09:12)
Corporate News - Zydus... - <P>Zydus Lifesciences has rece...
-
02-Jun-2025( 10:47)
Hot Pursuit - Zydus... - <p> Rifaximin tablets are indi...
-
28-May-2025( 01:23)
Hot Pursuit - Zydus... - The fast track designation is...
-
26-May-2025( 08:31)
Hot Pursuit - Zydus... - The approved drug is the gener...
Navigate The Market With Confidence
Your all-in-one destination for expert investment guidance and streamlined portfolio management solutions
Financials
All Values are in (₹Cr)Particulars(INCOME) | 2024 Mar | 2023 Mar | 2022 Mar | 2021 Mar | 2020 Mar | 2019 Mar |
---|---|---|---|---|---|---|
INCOME : | ||||||
Sales Turnover | 10,818.70 | 8,731.60 | 7,836.90 | 7,780.00 | 6,347.40 | 6,037.40 |
Excise Duty | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Sales | 10,818.70 | 8,731.60 | 7,836.90 | 7,780.00 | 6,347.40 | 6,037.40 |
Other Income | 1,084.80 | 548.40 | 178.70 | 89.30 | 908.70 | 605.20 |
Stock Adjustments | 131.70 | -105.10 | 46.90 | 148.30 | -15.50 | 86.00 |
Total Income | 12,035.20 | 9,174.90 | 8,062.50 | 8,017.60 | 7,240.60 | 6,728.60 |
EXPENDITURE : | ||||||
Raw Materials | 3,284.60 | 3,066.20 | 2,917.10 | 2,499.70 | 1,936.20 | 1,950.20 |
Power and Fuel Cost | 298.20 | 278.60 | 245.20 | 193.20 | 208.40 | 200.20 |
Employee Cost | 1,507.50 | 1,321.90 | 1,204.90 | 1,147.30 | 1,077.40 | 961.20 |
Other Manufacturing Expenses | 347.20 | 332.50 | 381.10 | 363.40 | 327.30 | 347.00 |
Selling and Administration Expenses | 1,016.00 | 1,039.80 | 958.40 | 1,009.10 | 925.30 | 755.00 |
Miscellaneous Expenses | 446.80 | 336.90 | 578.30 | 594.40 | 486.20 | 280.00 |
Employee Benefit Expenses | 1,507.50 | 1,321.90 | 1,204.90 | 1,147.30 | 1,077.40 | 961.20 |
Less: Preoperative Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Total Expenses | 6,900.30 | 6,375.90 | 6,285.00 | 5,807.10 | 4,960.80 | 4,493.60 |
Operating Profit | 5,134.90 | 2,799.00 | 1,777.50 | 2,210.50 | 2,279.80 | 2,235.00 |
Interest | 390.70 | 278.20 | 134.90 | 70.90 | 233.90 | 89.60 |
Gross Profit | 4,744.20 | 2,520.80 | 1,642.60 | 2,139.60 | 2,045.90 | 2,145.40 |
Depreciation | 504.40 | 488.60 | 478.70 | 451.10 | 428.90 | 358.20 |
Profit Before Tax | 4,239.80 | 2,032.20 | 1,163.90 | 1,688.50 | 1,617.00 | 1,787.20 |
Current Tax | 934.30 | 461.80 | 260.20 | 303.30 | 164.10 | 335.40 |
Fringe Benefit tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Deferred Tax | -136.00 | 41.20 | 45.80 | -91.00 | 40.00 | -33.90 |
Reported Net Profit | 3,441.50 | 1,529.20 | 857.90 | 1,476.20 | 1,412.90 | 1,485.70 |
Extraordinary Items | 3.90 | -92.27 | -237.64 | -156.95 | -52.67 | 74.44 |
Adjusted Net Profit | 3,437.60 | 1,621.47 | 1,095.54 | 1,633.15 | 1,465.57 | 1,411.26 |
Adjustment below Net Profit | -54.00 | 1.80 | -6.90 | -15.30 | -6.00 | -294.40 |
P & L Balance brought forward | 10,567.40 | 9,289.40 | 8,796.90 | 7,336.00 | 6,645.70 | 5,812.70 |
Statutory Appropriations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Appropriations | 607.30 | 253.00 | 358.50 | 0.00 | 716.60 | 358.30 |
P & L Balance carried down | 13,347.60 | 10,567.40 | 9,289.40 | 8,796.90 | 7,336.00 | 6,645.70 |
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Preference Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Equity Dividend (%) | 300.00 | 600.00 | 250.00 | 350.00 | 350.00 | 350.00 |
Dividend Per Share(Rs) | 3.00 | 6.00 | 2.50 | 3.50 | 3.50 | 3.50 |
Earnings Per Share-Unit Curr | 34.21 | 15.11 | 8.38 | 14.42 | 13.80 | 14.51 |
Earnings Per Share(Adj)-Unit Curr | 34.21 | 15.11 | 8.38 | 14.42 | 13.80 | 14.51 |
Book Value | 156.23 | 134.78 | 129.30 | 124.46 | 109.96 | 83.68 |
Book Value(Adj)-Unit Curr | 156.23 | 134.78 | 129.30 | 124.46 | 109.96 | 83.68 |